How Body Weight Affects Immune Response to COVID-19
Being overweight can impair the body’s antibody response to SARS-CoV-2 infection, but not to the protection offered by vaccination.
Being overweight can impair the body’s antibody response to SARS-CoV-2 infection, but not to the protection offered by vaccination.
A trial emulation study of veterans with COVID-19 found that the use of the antiviral nirmatrelvir–ritonavir (Paxlovid) was not effective for reducing the risk for many post-COVID-19 conditions.
The American Lung Association Research Institute awarded $13.6 million in research grants to fund 129 projects to advance science and lessen the burden of lung disease.
The FDA amended the emergency use authorization of the Novavax COVID-19 vaccine, adjuvanted to include the 2023-2024 formula.
Read MoreThough previous studies have shown that SARS-CoV-2 can directly infect tissues such as the lungs and brain, less was known about its effect on the coronary arteries.
Read MoreCell therapy has been shown to significantly reduce the mortality risk in COVID-19 patients based on an analysis of nearly 200 clinical trials conducted since 2020.
Read MoreResearchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read MorePart of NIH’s STRIVE consortium, the therapeutic may prevent overactive immune systems from causing severe symptoms.
Read MoreACP issued four practice points on the pharmacologic and biologic treatment of COVID-19 in the outpatient setting, endorsing two drugs and advising against two others.
Read MoreCough characteristics in COVID-19 patients could offer a quick and cost-effective method for identifying the severity of the disease in patients.
Read MoreThe ongoing ACTIV-6 study found that fluvoxamine, even at increased dosages, offers no clinical benefit in treating mild-to-moderate COVID-19 symptoms.
Read MoreA new SARS-CoV-2 vaccination designed to induce the production of Immunoglobulin A orally in monkeys produced the necessary antibodies against the disease without discernable side effects.
Read MoreThe mRNA vaccines are formulated to more closely target currently circulating variants by including a monovalent component that corresponds to the Omicron variant XBB.1.5.
Read MoreThe companies also filed an application with the FDA requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.
Read MoreIn a mouse study, researchers found that the vaccine prompted a robust immune response similar to levels seen with existing mRNA vaccines.
Read More